{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "QUIT",
  "name": "Achieve Life Sciences, Inc.",
  "url": "https://frontierpicks.com/dossiers/QUIT/",
  "json_url": "https://frontierpicks.com/dossiers/QUIT.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "AchieveRx (formerly Achieve Life Sciences) says its cytisinicline resubmission to the FDA is on track for the fourth quarter of 2026, with approval possible by mid-2027. The filing itself, naming Adare as manufacturer, settles whether that timetable holds.",
  "invalidation_trigger": "A daily close below $5.75, next to the 200-day average of $5.69, which would show the market doubting the refiling timetable. The case also breaks if the NDA resubmission slips out of the fourth quarter of 2026 or the FDA raises a non-manufacturing issue.",
  "catalyst_date": null,
  "portfolio": null,
  "pick": null,
  "themes": [
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Achieve Life Sciences, Inc. rebranded as AchieveRx, The Quit Company on 2026-11-09; the shares trade on Nasdaq under the symbol QUIT and the CUSIP is unchanged.",
    "AchieveRx has no approved product and no product revenue; cytisinicline is its only drug candidate.",
    "Warrants for about 49.5 million shares at a $3.51 exercise price, issued in the April 2026 private placement, can be exercised until 20 trading days after any FDA approval; some were exercised in the third quarter of 2026.",
    "Quarterly net loss swings with non-cash revaluation of warrant liabilities: a $48.7 million charge in the second quarter of 2026 and a $6.9 million gain in the third quarter."
  ],
  "source_links": [
    {
      "title": "AchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates",
      "url": "https://www.biospace.com/press-releases/achieverx-reports-third-quarter-2026-financial-results-and-provides-business-updates",
      "date": null
    },
    {
      "title": "AchieveRx Reports Q3 Results; Cytisinicline NDA Resubmission On Track For Q4 2026",
      "url": "https://www.rttnews.com/3712685/achieverx-reports-q3-results-cytisinicline-nda-resubmission-on-track-for-q4-2026.aspx",
      "date": null
    },
    {
      "title": "November 10, 2026 - 8-K: Current report",
      "url": "https://ir.achieverx.com/sec-filings/all-sec-filings/content/0001193125-26-455404/achv-20261110.htm",
      "date": "2026-11-10"
    },
    {
      "title": "BioPharmaWatch",
      "url": "https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-rebrands-achieverx-quit-company",
      "date": null
    },
    {
      "title": "ACHIEVE LIFE SCIENCES, INC. - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0000949858/000119312526344571/achv-ex99_1.htm",
      "date": "2026-08-11"
    }
  ],
  "evidence": [
    {
      "claim": "Third-quarter 2026 report: NDA resubmission on track for Q4 2026, potential FDA approval by end of Q2 2027; three commercial-scale stability batches completed at Adare.",
      "source": "AchieveRx Q3 2026 results release, 8-K exhibit 99.1",
      "as_of": "2026-11-10"
    },
    {
      "claim": "Cash, cash equivalents and marketable securities were $201.5M at 2026-09-30 versus $187.3M at 2026-06-30, up mainly on warrant exercises.",
      "source": "AchieveRx Q3 2026 results release",
      "as_of": "2026-09-30"
    },
    {
      "claim": "Q3 2026 operating expenses were $20.5M (R&D $6.2M, G&A $14.3M); net loss $12.1M ($0.11 per share) including a $6.9M non-cash warrant-liability gain; nine-month net loss $97.0M.",
      "source": "AchieveRx Q3 2026 results release",
      "as_of": "2026-09-30"
    },
    {
      "claim": "FDA issued a complete response letter citing cGMP observations at a prior third-party manufacturing facility and incomplete final labeling; the company said no efficacy or safety deficiencies were identified.",
      "source": "Q2 2026 results, 8-K exhibit 99.1",
      "as_of": "2026-06-20"
    },
    {
      "claim": "ORCA-OL: four-week continuous abstinence rose from 25.5% (weeks 9-12) to 31.2% (weeks 49-52) among 479 adults; no new safety signals.",
      "source": "AchieveRx Q3 2026 results release; CHEST 2026 presentation",
      "as_of": "2026-10-21"
    },
    {
      "claim": "Company rebranded as AchieveRx, The Quit Company and began trading under the symbol QUIT.",
      "source": "Company press release, 2026-11-09",
      "as_of": "2026-11-09"
    },
    {
      "claim": "Private placement of up to $354M: $180M upfront from 49.4M shares at $3.635, plus 49.5M warrants at $3.51.",
      "source": "Company 8-K exhibit 99.1",
      "as_of": "2026-04-16"
    }
  ],
  "view_changes": [],
  "body_markdown": "## Current Thesis\n\nAchieveRx's smoking-cessation drug, cytisinicline, can still reach FDA approval by mid-2027, and the shares are more likely than not to beat the S&P 500 over the next three months if the refiling lands on schedule. The FDA rejected the drug in June 2026 over a former manufacturer's plant and incomplete labeling, and the company says it identified no efficacy or safety deficiency. A new drug application (NDA) resubmission naming Adare Pharma Solutions as finished-product manufacturer, planned for the fourth quarter of 2026, decides the case.\n\nThe company reported third-quarter results on 2026-11-10 and said the resubmission remains on track for the fourth quarter of 2026, with potential FDA approval by the end of the second quarter of 2027 (company release, 2026-11-10). The same report said Adare had completed three commercial-scale stability batches. The company rebranded as AchieveRx, The Quit Company on 2026-11-09, and the shares now trade under the symbol QUIT.\n\nThe shares closed at $6.40 on 2026-11-10, the day of the report, against $6.78 on 2026-11-09, and at $6.45 on 2026-11-11. The report confirmed the timetable without lifting the price. The next fact that matters is the resubmission announcement itself.\n\n## Bull Case\n\n- **The timetable held at the third-quarter report.** On 2026-11-10 the company said the NDA resubmission is on track for the fourth quarter of 2026, with potential approval by the end of the second quarter of 2027. The 2026-08-11 report had set the same dates.\n- **Adare has moved past the first batch.** The 2026-11-10 release says Adare completed three commercial-scale stability batches. On 2026-08-11 the company had reported one engineering batch.\n- **The rejection centered on the plant.** The complete response letter (CRL), received 2026-06-20, cited current Good Manufacturing Practice observations at a prior third-party facility and labeling not finished by the action date. The company said the FDA identified no efficacy or safety deficiencies (second-quarter report, 2026-08-11).\n- **Cash rose in the quarter.** Cash, cash equivalents and marketable securities were $201.5 million on 2026-09-30, against $187.3 million on 2026-06-30. The company attributed the increase mainly to warrant exercises (2026-11-10 release).\n- **Quit rates rose over a year.** In the open-label ORCA-OL study, four-week continuous abstinence rose from 25.5% in weeks 9–12 to 31.2% in weeks 49–52 among 479 adults who had failed an earlier quit attempt. The company reported no new safety signals from the study's Data Safety Monitoring Committee (2026-11-10 release; CHEST 2026 presentation, 2026-10-21).\n- **Launch staffing is in place.** Benjamin Halladay became chief financial officer on 2026-10-01 and Kaitlyn Tuson became senior vice president of marketing and communications on 2026-10-07 (company releases).\n- **A second indication carries FDA priority status.** The vaping-cessation program has Breakthrough Therapy designation and a Commissioner's National Priority Voucher, and the end-of-Phase 2 meeting has been held (2026-11-10 release).\n\n## Bear Case\n\n- **Registration batches are not reported.** The 2026-11-10 release mentions stability batches at Adare and no registration batches. The release lists a possible FDA pre-approval inspection of Adare or other manufacturers among its risk factors.\n- **A dispute with Sopharma AD is disclosed.** The 2026-11-10 release cites a dispute with Sopharma AD and gives no detail. The release does not say what the dispute concerns.\n- **Overhead is rising with no revenue.** Third-quarter operating expenses were $20.5 million against $14.7 million a year earlier, and general and administrative expense was $14.3 million against $9.4 million. Nine-month 2026 net loss was $97.0 million (2026-11-10 release). Cytisinicline is the only drug candidate and there is no product revenue.\n- **Cheap stock overhangs the shares.** The April 2026 placement sold 49.4 million shares at $3.635 and attached 49.5 million warrants at $3.51 (company 8-K, 2026-04-16). Warrant exercises in the third quarter added cash and, by the same mechanism, new shares.\n- **Generic competition shapes pricing.** Cytisinicline would launch against generic varenicline, which could restrain launch pricing and payer coverage in 2027.\n\n## Setup & Price Structure\n\nThe shares closed at $6.45 on 2026-11-11. That is 25.3% below the 52-week high of $8.64, reached intraday on 2026-09-03, and 11.0% lower than three months earlier, on adjusted daily closes. The 52-week closing low was $2.65 on 2026-03-27.\n\nThe close sits below the 50-day average of $7.22 and above the 200-day average of $5.69, both as of 2026-11-11. Closes since 2026-11-04 have ranged from $6.38 on 2026-11-05 to $6.98 on 2026-11-04.\n\nThe market has priced in a refiling on time but not an approval: the shares fell 11.0% over the three months to 2026-11-11 while the company held its fourth-quarter 2026 refiling date at two successive quarterly reports.\n\n## Catalyst Calendar\n\n- **~2026-12-31 (est.):** NDA resubmission for cytisinicline naming Adare as finished-product manufacturer. The company has said the refiling is on track for the fourth quarter of 2026; it is the gating step toward a first-half 2027 approval, and a slip into 2027 delays the whole timeline.\n- **~2027-06-30 (est.):** Potential FDA approval of cytisinicline. The company anticipates approval by the end of the second quarter of 2027; approval would allow a US launch and set the 20-trading-day window for exercising the remaining April 2026 warrants.\n\n## What Would Change Our Mind\n\nA daily close below $5.75, next to the 200-day average of $5.69, which would show the market doubting the refiling timetable. The case also breaks if the NDA resubmission slips out of the fourth quarter of 2026 or the FDA raises a non-manufacturing issue.\n\nThe risks this note tracks, each with what would confirm it:\n\n- The NDA resubmission slips past the fourth quarter of 2026. Confirmed by: A company update moving the refiling into 2027, or no resubmission announcement by the first quarterly report of 2027.\n- Manufacturing problems at Adare delay the filing or trigger a second complete response letter. Confirmed by: Disclosure of failed registration batches, missing stability work or adverse FDA inspection findings at Adare.\n- The dispute with Sopharma AD, cited in the 2026-11-10 release, affects supply or rights to cytisinicline. Confirmed by: A company filing or release describing the dispute's subject, a legal claim, or a change in the licence terms.\n- Placement investors and warrant holders sell into strength, or the company issues new shares. Confirmed by: Form 4 or 13D/G filings showing reduced stakes by lead investors, a registered resale, or a new share offering.\n- Rising overhead shortens the funding runway before launch. Confirmed by: Quarterly operating expenses above the $20.5 million of the third quarter of 2026 without a matching rise in cash from warrant exercises.\n- Generic varenicline restrains pricing and payer coverage at launch. Confirmed by: Restrictive formulary placement or a launch price below company expectations in 2027 commercial disclosures.\n\n## Correlation Notes\n\nThe shares trade on company-specific regulatory news. The CRL, the Adare transfer and the refiling date move them more than the broad market. Reported earnings also swing with the warrants, which are carried as a liability: the second quarter included a $48.7 million non-cash warrant charge, and the third quarter included a $6.9 million non-cash gain (company releases, 2026-08-11 and 2026-11-10). Headline losses therefore say little about the cash cost of running the business.",
  "first_seen": "2026-10-12",
  "last_analyzed": "2026-11-12T03:38:30+00:00",
  "last_synthesized": "2026-11-12",
  "date_modified": "2026-11-12",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}